ANGELALIGN Wins Patent Case as European Court Dismisses Align Technology's Infringement Claims

Stock News05-14

On May 12, ANGELALIGN announced that it appreciates the ruling by the Local Division of the Unified Patent Court in Düsseldorf, Germany, which dismissed Align Technology's request to prohibit ANGELALIGN from using its A7 premolar extraction solution. The company stated that its A7 premolar extraction solution has never infringed upon any patents claimed by Align Technology. ANGELALIGN expressed its respect for the court's decision to reject Align's request for a preliminary injunction against the use of this solution.

Dr. Arno Riße, the legal representative from Arnold Ruess law firm in Düsseldorf, stated, "We respect the ruling of the Düsseldorf Local Division and will continue to argue that ANGELALIGN has not infringed any valid patents. We are grateful that the court did not support Align Technology's request for provisional measures. ANGELALIGN places high importance on intellectual property and consistently ensures that it does not infringe upon any valid patent rights."

Richard Hirschland, Chief Commercial Officer and Senior Vice President of ANGELALIGN, added, "We firmly deny the allegations of infringement and are confident in our position. We look forward to continuing to share the success story of ANGELALIGN through this litigation and to helping the company attract more global customers."

With over two decades of clinically-driven innovation, ANGELALIGN takes pride in consistently leading innovation in the invisible orthodontics industry. The company's cutting-edge products include the award-winning angelButton solution, angelHook solution, the A6 mandibular advancement solution (celebrating its tenth anniversary), the angel KiD pediatric solution, and the Intelligent Root and Bone System (IRS). Committed to fostering fair and healthy market competition, ANGELALIGN aims to create value for both doctors and patients.

The company's products have long received high satisfaction ratings from doctors. Its flexible manufacturing system is widely recognized for transforming complex clinical concepts into practical solutions. Driven by its innovative achievements and a corporate culture that values employees and customers, ANGELALIGN has achieved remarkable and robust growth in the global market and intends to maintain this momentum.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment